House Hearing Probes FDA’s Cosmetics Role
This article was originally published in The Rose Sheet
Stakeholders from industry, government and FDA discussed ideas for changing the agency’s oversight of cosmetics at a House subcommittee meeting March 27. The need for a national regulatory system, mandatory recalls, company and ingredient registration and adverse event reporting were debated.
You may also be interested in...
House Energy & Commerce Committee Chairman Frank Pallone underscores FDA’s lack of resources and insufficient “regulatory tools” in a memo to Health Subcommittee members going into a 4 December hearing on cosmetics safety issues. The committee’s last hearing on the subject was in 2012 when Pallone unveiled the first version of his Cosmetics Safety Enhancement Act.
The Safe Cosmetics and Personal Care Products Act, reintroduced in the US House, exceeds the proposed Personal Care Products Safety Act in the Senate in terms of the duties and resource demands it would impose on companies and the FDA, while leaving states free to regulate cosmetics even more stringently. The proposal now must vie for the attention of the Energy and Commerce Committee.
Since 2012 when a House committee held the last cosmetics hearing, industry generally has warmed to – or resigned itself to – legislative proposals to update the cosmetics regulatory system. However, there is still not consensus on the details among big business, SMEs and consumer advocates, all of which will be represented at the Senate HELP Committee’s witness table.